TSC2 normally function to suppress the mechanistic target of rapamycin 1 (mTORC1) pathway, abnormal mTORC1 hyperactivation in TSC promotes increased cellular growth and proliferation, leading to tumor or hamartoma formation in multiple organs such as the brain, eyes, skin, heart, lungs, and kidneys. [4] [5] [6] In the brain, focal lesions, including cortical tubers and subependymal giant cell astrocytomas, are characteristic and may contribute to neurologic symptoms in patients with TSC. In particular, cortical tubers, which represent focal malformations of cortical development, are often thought to be the foci for epileptic seizures. Despite the potential role of tubers as gross structural lesions in causing neurologic manifestations of TSC, the cellular pathophysiology of epilepsy and cognitive dysfunction remains unclear. Furthermore, independent of tubers, there is increasing evidence that more remote, nonlesional (ie, structurally normal on MRI) brain regions may also contribute to or cause the neurologic phenotypes of TSC. 7 Not surprisingly, on the cellular level, abnormalities in neurons have been strongly implicated in TSC pathophysiology, including physiologic defects as well as morphologic abnormalities, such as in the form of the classic dysmorphic neurons seen in TSC brains. 8 In addition, increasing evidence from both animal models and human TSC tissue suggests that physiologic and pathologic abnormalities in astrocytes also play a major role in contributing to neurologic phenotypes of TSC. 9, 10 Microglia are another cell type that has been increasingly implicated in neurologic disorders, including TSC. Microglia act as resident macrophages and are involved in innate immunity and inflammatory responses in the brain. 11, 12 In addition, microglia participate in other basic processes related to brain development and function, such as synaptogenesis and synaptic pruning. 13 However, microglia can also assume a pathologic state of activation, involving increased cell size and number, that may contribute to the pathophysiology of some neurologic disorders. In TSC patients, pathologic abnormalities in microglia have been demonstrated in cortical tuber specimens, 14, 15 but whether microglia are primary contributors to epilepsy and other neurologic dysfunction in TSC or are part of a secondary, reactive process has not been definitively established. A recent study indicates that microglia abnormalities could be a primary cause of epilepsy in TSC. 16 In the present study, we similarly aim to determine whether Tsc1 gene inactivation in microglia is sufficient to cause epilepsy using mouse models of TSC.
| MATERIALS AND METHODS

| Animals and drug treatment
Care and use of all mice were conducted according to an animal protocol approved by the Washington University (CAG-ZsGreen1)Hze /J (Rosa-Green; Jackson Laboratory) reporter mice were crossed with Cx3cr1-Cre or Cx3cr1-CreER mice to confirm the cellular localization of Cre-mediated recombination with or without tamoxifen treatment. Genotyping was performed for Cx3cr1-Cre according to the protocol from the Jackson Laboratory website and for Tsc1-flox as described previously. 9 Briefly, toes were cut and lysed with protease K (Sigma, St. Louis, Missouri), DNA was extracted, and polymerase chain reaction (PCR) amplification was used to genotype mice by detection of sequences not normally present in the genome.
In some experiments, 3-week-old Tsc1 
| Western blotting
Western blot analysis was used to measure protein levels of P-S6 in the brains of Tsc1
Cx3cr1-Cre
CKO, Tsc1
Cx3cr1-CreER CKO, and control mice as a measure of mTORC1 activity, using standard methods as described previously. 20 Briefly, the entire neocortex and hippocampus were dissected and homogenized separately. Equal amounts of total protein extract were separated by gel electrophoresis and transferred to nitrocellulose membranes. After being incubated with primary antibodies to P-S6 (Ser240/244) or S6 (#2215, #2217, Cell Signaling Technology, Danvers, Massachusetts), the membranes were reacted with a peroxidaseconjugated secondary antibody (#7074, Cell Signaling Technology). Signals were detected by enzyme chemiluminescence (GE Healthcare Life Science, Pittsburgh, Pennsylvania) and quantitatively analyzed with ImageJ software (NIH, Bethesda, Maryland).
| Immunohistochemistry
Histologic analysis was performed in a blinded fashion to assess microglia cell size and number by standard methods, as described previously. 20 In brief, brains were perfusionfixed with 4% paraformaldehyde and cut into 45 μm sections with a cryotome. Immunohistochemistry was performed for Iba1 to assess microglial cells by labeling with primary antibody, anti-Iba1 (#019-19741 Wako, Richmond, Virginia), followed by labeling with secondary antibody Alexa-488 conjugated goat anti-rabbit IgG (#A11034, Life Technologies, Carlsbad, California). In addition, sections were counterstained with TO-PRO-3 Iodide (Life Technologies) for the nonspecific nuclear staining of all cells. In other experiments, after Iba1 staining, double labeling for P-S6 was undertaken with primary anti-P-S6 antibody (#2217, Cell Signaling Technology) followed by Cy3-conjugated goat anti-rabbit IgG (#A10520, Life Technologies).
Images were acquired with a Zeiss LSM PASCAL confocal microscope (Zeiss, Thornwood, New York). 
| Video-electroencephalography monitoring and seizure threshold testing
Vehicle-and rapamycin-treated Tsc1
Cx3cr1-Cre CKO mice or tamoxifen-treated Tsc1 Cx3cr1-CreER CKO mice underwent video-EEG monitoring starting at 3 weeks of age (48 hours at 3 weeks, and then continuous 24/7 starting at 4 weeks), using established methods for implanting epidural electrodes and performing continuous video-EEG recordings, as described previously. 21, 22 Briefly, mice were anesthetized with isoflurane and placed in a stereotaxic frame. Epidural screw electrodes were surgically implanted and secured using dental cement for long-term EEG recordings. Four electrodes were placed on the skull: one right and one left central electrode (1 mm lateral to midline, 2 mm posterior to bregma), one frontal electrode (0.5 mm anterior and 0.5 mm to the right or left of bregma), and one occipital electrode (0.5 mm posterior and 0.5 mm to the right or left lambda). The typical recording montage involved 2 EEG channels with the right and left central "active" electrodes being compared with either the frontal or occipital "reference" electrode.
Video and EEG data were acquired simultaneously with an AD Instruments PowerLab video-EEG system (AD Instruments, Sydney, Australia 
| Statistics
All statistical analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, California). Quantitative differences between groups were analyzed by Student's t -test, or one-way analysis of variance (ANOVA) with Tukey's multiple comparison post hoc tests. Chi-square test was used for survival analysis. Quantitative data are expressed as mean ± standard error of the mean (SEM). Statistical significance was defined as P < 0.05.
| RESULTS
| Microglial and mTORC1 activation in Tsc1
Cx3cr1-Cre CKO mice
To test the potential role of microglia in the neurologic phenotype of TSC, we first created a conventional conditional knockout mouse targeting Tsc1 gene inactivation with a Cx3cr1-Cre driver (Tsc1 Cx3cr1-Cre CKO mice), as Cx3cr1 represents a chemokine receptor that has been reported to be selectively expressed by microglia during embryonic brain development. 23, 24 Tsc1
Cx3cr1-Cre CKO mice were viable and initially appeared grossly normal.
Tsc1
Cx3cr1-Cre CKO mice demonstrated evidence of microglial activation, as seen by increased cell size and number of microglia as assayed by Iba1 immunohistochemistry (Figure 1 ). The increased microglial size and number were evident in 4-week-old Tsc1 Cx3cr1-Cre CKO mice in both neocortex and hippocampus and were at least partially reversible by the mTORC1 inhibitor rapamycin, indicating dependence on mTORC1. As additional evidence for the functional effect of Tsc1 inactivation in Tsc1
Cx3cr1-Cre CKO mice, mTORC1 activity was found to be increased in both neocortex and hippocampus of 4-week-old Tsc1
Cx3cr1-Cre CKO mice as assayed by Western blotting of downstream P-S6 expression, which was also blocked by rapamycin (Figure 2) .
Furthermore, coimmunostaining of P-S6 and Iba1 demonstrated abundant double-labeled cells, which were increased in size and number in 4-week-old Tsc1
Cx3cr1-Cre CKO mice (KO) compared with control mice (Cont), indicating that mTORC1 activity was increased in KO microglia ( Figure S1 ).
| mTORC1-dependent megalencephaly, epilepsy, and decreased survival in Tsc1
Cx3cr1-
Cre CKO mice
Tsc1
Cx3cr1-Cre CKO mice exhibited diffuse megalencephaly of the brain, as grossly visible and also reflected by increased brain weight at 4 weeks of age ( Figure 3A) , which was prevented by rapamycin treatment. Vehicle-treated Tsc1 Cx3cr1-Cre CKO mice had significantly decreased body weight compared with vehicle-treated control mice at 4 weeks of age, but not 3 weeks of age, whereas rapamycin treatment did not prevent the decreased weight (Figure 3B) . Tsc1
Cx3cr1-Cre CKO mice were monitored for seizures with continuous video-EEG monitoring starting at 3 weeks of age. About 100% (12 of 12 mice) had documented clinical-electrographic seizures, as well as interictal bursts of spikes ( Figure 4A) . Behaviorally, the seizures were characterized primarily by rearing up and repetitive forelimb clonus. Electrographically, the seizures demonstrated stereotypic development of repetitive spikes, which evolved in frequency and amplitude into periodic bursts, lasting at least 10 seconds, and followed by voltage suppression. Overall, average seizure frequency was relatively low (~one seizure/week), but individual mice tended to develop acute clusters of seizures between 4 and 9 weeks of age, correlating with a rapid onset of premature death ( Figure 4B ). About 50% of Tsc1
Cx3cr1-Cre CKO mice had died by about 5 weeks of age, and all by 13 weeks (Figure 4C) . Most mice were documented on video-EEG to die in the context of or immediately after a seizure. Rapamycin treatment initiated at 3 weeks of age almost completely suppressed the development of seizures and prolonged survival, with all rapamycin-treated Tsc1
Cx3cr1-Cre CKO mice surviving to at least 12 weeks of age ( Figure 4B,C) . However, once rapamycin was ZHANG ET AL.
| 1799 stopped at 12 weeks of age, seizures subsequently occurred in some mice, and all mice died by 24 weeks of age ( Figure 4B ,C).
| Specificity of constitutive Cx3cr1-Cre versus inducible Cx3Cr1-CreER for microglia
The documentation of robust seizures in 100% of Tsc1 Cx3cr1-Cre CKO mice provides initial evidence that Tsc1 inactivation in microglia is sufficient to cause epilepsy, but this assumes that the Cx3cr1-Cre driver is specific for microglia. To test for cellular specificity, we crossed RosaGreen Cre reporter mice with our Cx3cr1-Cre mice to confirm the cellular localization of Cre-mediated recombination. In a quantitative analysis, the expression of the GFP reporter gene was detected in almost 90% of Iba1-positive cells in hippocampus and cortex, indicating a high efficiency of Cre recombination within microglia (Figure S2) . However, when double labeling for other cellular markers, a large percentage of other Rosa-Green-positive cells were identified that were negative for Iba1, but positive for NeuN or to a lesser degree GFAP, indicating that neurons and some astrocytes were also affected by Cre recombination. Hence, the Cx3cr1-Cre does not appear to be specific for microglia, at least under conditions of constitutive expression, which includes the prenatal embryonic period. Thus although microglia may contribute to an epilepsy phenotype, it is difficult to conclude that Tsc1
F I G U R E 1 Microglial activation in Tsc1
Cx3cr1-Cre CKO mice. Tsc1 Cx3cr1-Cre CKO mice exhibit increased microglial cell size and number.
Microglial activation was assessed by Iba1 (green) immunohistochemistry, followed by counterstaining with TO-PRO-3 Iodide (blue) for the nonspecific nuclear staining of all cells, in neocortex (A) and hippocampus (D). Four-week-old Tsc1
Cx3cr1-Cre CKO mice (KO+Veh) had significantly increased Iba1-positive cell size and number in neocortex (B,C) and hippocampus (E,F), compared with control mice (Cont+Veh). Rapamycin treatment (3 mg/kg/day ip for 1 week starting at 3 weeks of age) of Tsc1 Cx3cr1-Cre CKO mice (KO+Rap) significantly reduced the Iba1-positive cell size and number, except for that of cell number in hippocampus (F). *P < 0.05, **P < 0.01, ***P < 0.001, by one-way ANOVA (n = 5-6 mice/group). Cont, control mice; KO, Tsc1 Cx3cr1-Cre CKO mice; Veh, vehicle; Rap, rapamycin. Scale bar = 50 μm inactivation in microglia in itself is solely responsible for causing seizures in conventional Tsc1 Cx3cr1-Cre CKO mice.
Although the above studies indicate that constitutive Cx3cr1-driven inactivation may not be microglia-specific, it is possible that temporally targeted, postnatal Cx3cr1 expression may be more specific for microglia, such as in using an inducible Cx3cr1-CreER that can be activated by tamoxifen injection postnatally. To test this possibility, Rosa-Green Cre reporter mice were crossed with Cx3cr1-CreER mice and injected with tamoxifen starting at
F I G U R E 2 mTORC1 activation in Tsc1
Cx3cr1-Cre CKO mice.
mTORC1 activation was assessed by Western blotting of protein expression of P-S6 and S6 in the neocortex (A) and hippocampus (B) of Tsc1
Cx3cr1 CKO mice, and the effect of rapamycin was tested. Four-
week-old Tsc1
Cx3cr1-Cre CKO mice (KO+Veh) had significantly increased P-S6 levels compared with control mice (Cont+Veh). Rapamycin treatment (3 mg/kg/day, ip for 7 days) significantly decreased P-S6 levels in Tsc1 Cx3cr1-Cre CKO mice (KO+Rap). The ratio of P-S6/S6 was normalized to the vehicle-treated control group. *P < 0.05, **P < 0.01, by one-way ANOVA (n = 8 mice/group). Cont, control mice; KO, Tsc1 Cx3cr1-Cre CKO mice; Veh, vehicle; Rap, rapamycin
F I G U R E 3 Megalencephaly and decreased body weight in
Tsc1
Cx3cr1-Cre CKO mice. A, Tsc1 Cx3cr1-Cre CKO mice (KO+Veh) exhibited diffuse megalencephaly of the brain, as grossly visible and also reflected by increased brain weight at 4 weeks of age, compared with control mice (Cont+Veh). Rapamycin treatment (3 mg/kg/day, ip for 7 days) significantly decreased brain weight in Tsc1 Cx3cr1-Cre CKO mice (KO+Rap). Scale bar = 5 mm.
***P < 0.001 by one-way ANOVA (n = 9-10 mice/group). B, Body weight of mice of each group at 3 and 4 weeks of age. There was no significant difference in body weight between groups at 3 weeks of age. At 4 weeks, Tsc1 Cx3cr1-Cre CKO mice (KO + Veh) had significantly decreased body weight compared with control mice (Cont+Veh). Rapamycin treatment did not reverse this decreased body weight, *P < 0.05, **P < 0.01, by one-way ANOVA (n = 8 mice/group). Cont, control mice; KO, Tsc1 Cx3cr1-Cre CKO mice; Veh, vehicle; Rap, rapamycin 2 weeks of age. Similar to Cx3cr1-Cre mice without tamoxifen, the efficiency of Cre expression was around 90% in cortex and hippocampus in Cx3cr1-CreER mice following tamoxifen injection ( Figure S3 ). Moreover, in contrast to constitutive Cx3cr1-Cre mice, inducible Cx3cr1-CreER appeared to be more specific to microglia as seen in Iba1 double labeling compared with NeuN and GFAP, although about 5% of neurons in cortex still showed evidence of Cre recombination. Thus compared with Tsc1
Cx3cr1-Cre CKO mice, postnatally activated Tsc1
Cx3cr1-CreER CKO mice are more appropriate for testing the role of microglia in neurologic phenotypes of TSC.
| Tsc1
Cx3cr1-CreER CKO mice demonstrate microglia and mTORC1 activation, but do not have epilepsy
Tsc1
Cx3cr1CreER CKO mice injected with tamoxifen starting at 2 weeks of age were first analyzed for evidence of microglial activation. Similar to conventional Tsc1 Cx3cr1-Cre CKO mice, microglia in cortex and hippocampus had both increased cell size and number following tamoxifen injection in Tsc1 Cx3cr1-CreER CKO mice ( Figure 5 ). Correspondingly, mTORC1 activation was increased in cortex and hippocampus of Tsc1
Cx3cr1-CreER CKO mice, as reflected by downstream P-S6 expression ( Figure 6 ). However, in contrast to Tsc1
Cx3cr1-Cre CKO mice, continuous video-EEG monitoring for up to 6 months following tamoxifen injection did not detect any seizures in Tsc1
Cx3cr1-CreER CKO mice or any definite interictal epileptiform abnormalities in all mice ( Figure S4A , n = 9 mice recorded continuously for at least 10 weeks after tamoxifen, range 10-26 weeks, mean 16.0 ± 2.5 weeks; an additional 2 mice recorded for 3-4 weeks after tamoxifen). Furthermore, there was no significant difference between 8-week-old tamoxifen-and vehicle-injected Tsc1 one-way ANOVA (n = 12 mice/group). C, Survival analysis showed that vehicle-treated Tsc1 Cx3cr1-Cre CKO mice die prematurely with 50% mortality at 5-6 weeks of age and 100% mortality by 13 weeks, while all rapamycin-treated mice survived during rapamycin treatment. ***P < 0.001 by chi-square test, comparing the 2 groups (n = 12 mice/group). However, once rapamycin was stopped at 12 weeks of age (arrows in B and C), seizures subsequently occurred in some mice, and all mice died by 24 weeks of age. Cont, control mice; KO, Tsc1 Cx3cr1-Cre CKO mice; Veh, vehicle; Rap, rapamycin mice per group). In addition, there was no evidence of megalencephaly or significantly increased brain weight in tamoxifeninjected Tsc1
Cx3cr1-CreER CKO mice ( Figure S4C , brain weight = 458.2 ± 13.0 in tamoxifen-injected mice vs 434.5 ± 7.0 in vehicle-injected mice). Thus, in contrast to the Tsc1 Cx3cr1-Cre CKO mice, which lacked microglia specificity, the more microglia-selective Tsc1
Cx3cr1-CreER CKO mouse did not provide evidence that Tsc1 inactivation in microglia by itself is sufficient to cause epilepsy.
| DISCUSSION
The present study directly tests the hypothesis that Tsc1 gene inactivation and corresponding mTORC1 activation specifically in microglia are sufficient to cause an epilepsy phenotype in TSC mouse models. Using a constitutive Cx3cr1-Cre approach, Tsc1
Cx3cr1-Cre CKO mice demonstrate increased microglia size and number, mTORC1 hyperactivation, and robust epilepsy; however, the Cx3cr1 expression did not appear to be specific for microglia, but also directly involved a large percentage of cortical neurons, making it difficult to isolate the role of microglia in epileptogenesis. In contrast, utilizing an inducible Cx3cr1-Cre ER approach that was more selective for microglia, postnatal induction of Tsc1 inactivation led to similar microglial abnormalities and mTORC1 activation in cortex and hippocampus but no detectable epilepsy. Comparing the 2 models, it appears that Tsc1 inactivation in microglia alone, in the absence of neuronal involvement, may not be sufficient to cause epilepsy.
There has been accumulating evidence for a primary role of microglia in epileptogenesis, but this remains controversial and likely depends on the type or cause of epilepsy. Without doubt, microglial abnormalities have been reported in pathologic specimens from epilepsy patients and in multiple animal models of epilepsy. 25, 26 However, most of these findings are correlative and do not prove a primary role of microglia in contributing to epileptogenesis, as opposed to being a secondary response to seizures or an epiphenomenon. The most direct evidence for a primary role of microglia in causing epilepsy derives from animal models in which microglial activation can be reversed, typically by pharmacologic means, such as through the use of minocycline, an inhibitor of microglial activation. 27 Minocycline decreases epileptogenesis in rodent models of temporal lobe epilepsy. 28, 29 In TSC patients, abnormalities in microglia have been reported in cortical tuber specimens, 14, 15 but again whether these microglial abnormalities are primary or secondary in relation to epilepsy is unknown. In a previous study, a mouse model of TSC, involving inactivation of the Tsc1 gene in glia and neurons driven by a GFAP promoter (Tsc1 GFAP CKO mice), leads to increases in microglial cell size and number, which is reversible by minocycline. 20 However, the epilepsy in
Tsc1
GFAP CKO mice is not reversed by minocycline, indicating that the microglial reaction in this model is a secondary response.
In the present study, we adopted a genetic approach to directly test the primary role of microglia in epileptogenesis in TSC mouse models, using Cx3cr1-Cre to induce Tsc1 inactivation under the assumption that Cx3cr1 is specifically expressed in the brain in microglia. 23, 24 Although conventional Tsc1 Cx3cr1-Cre CKO did show a very high efficiency in affecting microglia, somewhat surprisingly Cre reporter mice studies did not confirm specificity for microglia but also indicated substantial direct neuronal involvement, confounding interpretation of the cellular origin of epilepsy in the Tsc1 Cx3cr1-Cre CKO mice. The Cx3cr1 promoter has been reported to be an appropriate driver for targeting microglia; however, the issue of microglial specificity of Cx3cr1 in the brain is not definitive, as recent reports have demonstrated Cx3cr1 expression in neurons, [30] [31] [32] suggesting that the use of a Cx3cr1 driver is not necessarily specific for microglia in the brain. Because many gene promoters are developmentally regulated and more active in certain cell types in early development before becoming silent, it is possible that specificity of Cxc3cr1 expression in microglia increases with age. In fact, utilizing an inducible Cxc3cr1-CreER with postnatal activation did appear to significantly increase microglia specificity in Tsc1 Cx3cr1ER CKO mice, but in our hands, this was not sufficient to cause epilepsy. By comparison, a recently published study also generated a similar Tsc1
Cx3cr1-Cre CKO mouse with comparable microglia abnormalities and robust seizures, leading the authors to conclude that specific microglia abnormalities were sufficient to cause epilepsy. 16 However, while the Cre driver in that study was stated to be specific for F I G U R E 6 Tamoxifen-induced mTORC1 activation in
Cx3cr1-CreER CKO mice. mTORC1 activation was assessed by
Western blotting of protein expressions of P-S6 and S6 in the neocortex (A) and hippocampus (B) of tamoxifen-treated Tsc1
Cx3cr1-CreER CKO mice and control mice. Starting at 2 weeks of age, tamoxifen was administered (9 mg/40 g body weight; ip) to mice every other day 5 times. Six weeks after tamoxifen treatment, Tsc1 Cx3cr1-CreER CKO mice had significantly increased P-S6 levels compared with vehicle-treated Tsc1 Cx3cr1-CreER CKO mice and control mice in both neocortex (A) and hippocampus (B). The ratio of P-S6/ S6 was normalized to the vehicle-treated control group. *P < 0.05, ***P < 0.001, by one-way ANOVA (n = 8 mice/group). Cont, control mice; KO, Tsc1 Cx3cr1-CreER CKO mice; Veh, vehicle; TM, tamoxifen microglia, quantitative analysis and, in particular, double labeling for neurons in their Cre reporter experiments were not reported, so it is possible that their model also had neuronal, as well as microglial, knockout of Tsc1, as we found in our quantitative Cre reporter studies with double labeling for microglia, neurons, and astrocytes. On the other hand, the previous study also tested the effect of postnatal induced, Cx3Cr1-CreER driven Tsc1 inactivation and, in contrast to our study, still found very robust seizures. 16 However, the previous study did not include any
Cre reporter data for postnatal Cre induction. By extrapolation, our quantitative reporter studies with postnatal Cre induction in Cx3cr1-Cre ER mice showed substantially increased microglia specificity compared with the conventional Tsc1
Cx3cr1-Cre CKO mouse, suggesting that postnatal microglial Tsc1 inactivation may have been sufficient to cause epilepsy in the previous study. 16 However, there was still a small percentage of cortical and hippocampal neurons demonstrating Cre recombination in our postnatal reporter studies, which in itself might be sufficient to cause epilepsy. For example, postnatal mTOR activation in less than 10% of dentate granule neurons has been shown previously to be sufficient to cause epilepsy. 33 Another difference between our studies was the source of the Cx3cr1-Cre mice and the genetic background, which could influence seizure susceptibility. However, if it is accepted that Cx3cr1 is expressed in neurons, [30] [31] [32] then these additional factors should not negate the underlying biologic principle that the use of Cx3cr1 as a Cre driver is not specific for microglia and the potential contribution of neurons cannot be ignored in these models. Finally, there could have been a difference in efficiency in microglia (or neuronal) Cre recombination in our respective inducibleCre mice between the 2 studies, but our detailed reporter studies document a very high efficiency of Cre recombination in microglia. Thus, based on the available data, it may still not be definitive whether any epilepsy phenotype reported with either pre-or postnatal Cx3Cr1-driven Tsc1 inactivation in the previous 16 or current study was specifically due to microglia abnormalities. In summary, with rigorous reporter data correlating microglia specificity and efficiency of Tsc1
Cx3cr1-Cre CKO mice and Tsc1 Cx3cr1-CreER CKO mice with the presence and absence of epilepsy, respectively, the most parsimonious conclusion with the currently available data is that Tsc1 inactivation in microglia alone may not be sufficient to cause epilepsy, but primary neuronal involvement may also be required. However, this does not exclude the possibility that microglia abnormalities contribute to or are necessary for epileptogenesis in the context of neuronal abnormalities. As a future direction, a "two-hit" model combining an acquired insult, such as a proinflammatory stimulus, in the Tsc1 Cx3cr1-CreER CKO mice, may be sufficient to cause epilepsy. Furthermore, while in our hands, postnatal inactivation of Tsc1 alone in Tsc1 Cx3cr1-CreER CKO mice was not sufficient to cause epilepsy; it is possible that prenatal microglia-specific Tsc1 inactivation may be sufficient to cause epilepsy, but unfortunately the constitutive Tsc1 Cx3cr1-Cre CKO mice with presumed embryonic induction could not test this possibility due to clear lack of specificity for microglia. Future studies and approaches that improve selectivity for targeting microglia embryonically may test this possibility more directly.
